Fosdevirine

Drug Profile

Fosdevirine

Alternative Names: '761; 2248761 - ViiV Healthcare; GSK2248761; GSK2248761A; IDX-12899; IDX-899

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer GlaxoSmithKline; ViiV Healthcare
  • Class Amides; Antivirals; Indoles; Nitriles; Phosphinic acids; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 15 Mar 2012 Fosdevirine is no longer licensed to ViiV Healthcare
  • 05 May 2011 GlaxoSmithKline terminates a phase I drug-interaction trial in the USA (NCT01195974)
  • 10 Feb 2011 The US FDA places a clinical hold on GSK 2248761 for the treatment of HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top